Cullinan stock rises on Amgen’s Blincyto data (NASDAQ:CGEM)

0


Business on Wall Street in Manhattan

Pgiam/iStock via Getty Images

Cullinan Therapeutics (NASDAQ:CGEM) drew Wall Street’s attention last week as William Blair touted the stock after peer-reviewed data for Amgen’s (NASDAQ:AMGN) leukemia therapy, Blincyto, which targets CD19 surface antigens on B cells similar to CGEM’s lymphoma candidate CLN-978.

Cullinan (



Source link

Leave A Reply

Your email address will not be published.